Illustration: Sarah Grillo/Axios

The Senate's drug pricing bill would likely be better for the pharmaceutical industry than either President Trump's agenda or House Speaker Nancy Pelosi's.

Between the lines: Industry opposes anything that would hurt its bottom line, but of those three proposals, the Senate's "is a positive tradeoff," analyst Ronny Gal of AllianceBernstein wrote to investors this week.

Between the lines: The Senate bill could take some political heat off the industry, while Pelosi's bill and Trump's proposal to tie Medicare's prices to international prices would make bigger changes to the actual system.

How it works: The international pricing index and Senate bill both only focus on Medicare, but would change different parts of Medicare.

  • The international pricing index would lower prices for Medicare Part B drugs, which are things like chemotherapy and eye drugs that are administered in doctors' offices. Regeneron, Roche, Amgen and Bristol-Myers Squibb generate the most revenue from Medicare Part B and therefore are most invested in killing that proposal.
  • The Senate bill would cap some prices for Medicare Part D drugs — the ones patients pick up from pharmacies. Celgene, Novo Nordisk, GlaxoSmithKline and AstraZeneca would feel the most pain to sales, according to Gal.
  • Because the Senate bill proposes the most temperate changes, the industry will push for that as the main political vehicle while mitigating the damage to companies most exposed to Part D.

Both of those proposals pale in comparison to Pelosi's bill, which would limit prices in all insurance plans, including the most lucrative commercial business.

  • Pelosi's bill would "be a fundamental change of business model for the drug industry," Gal wrote, and it's why pharmaceutical lobbyists and Senate Republicans have said it's a nonstarter.

Go deeper

Harris previews dual role in debut speech: Attacking Trump and humanizing Biden

Sen. Kamala Harris began her first speech as Joe Biden's running mate excoriating President Trump for his "mismanagement" of the coronavirus and scorn for the racial justice movement, before quickly pivoting to how she came to know Biden: through her friendship with his late son Beau.

Why it matters: The debut speech on Wednesday underscored the dual roles that Harris will take on for the rest of the campaign — humanizing Biden during a moment of national crisis and "prosecuting" the case against Trump as a failed president.

27 mins ago - Health

The two sides of America's coronavirus response

Illustration: Eniola Odetunde/Axios

America's bungled political and social response to the coronavirus exists side-by-side with a record-breaking push to create a vaccine with U.S. companies and scientists at the center.

Why it matters: America's two-sided response serves as an X-ray of the country itself — still capable of world-beating feats at the high end, but increasingly struggling with what should be the simple business of governing itself.

Joe Biden introduces Kamala Harris in first joint appearance

Joe Biden formally introduced Sen. Kamala Harris as his running mate on Wednesday, telling a socially distanced audience in a Wilmington, Del., gymnasium: "I have no doubt that I picked the right person to join me as the next vice president of the United States of America."

Why it matters: Harris is a historic pick for vice president, becoming the first Black woman and first South Asian woman to be named to a major-party U.S. presidential ticket. "Kamala knows how to govern," Biden said. "She knows how to make the hard calls. She is ready to do this job on day one."